Trial Profile
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Vinorelbine
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms DURATION
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 13 Jun 2023 Status changed from active, no longer recruiting to completed.
- 05 Oct 2022 Planned End Date changed from 1 Dec 2022 to 1 Jan 2024.